Cyrus Biotechnology Launches Levitate Bio to Broaden Access to Rosetta Drug Development Software

Seattle startup Cyrus Biotechnology has spun out a new for-profit company, Levitate Bio, owned by the Rosetta Commons Foundation, to expand access to its versatile drug development software platform, Rosetta. Levitate Bio, led by CEO Sam DeLuca and executive VP Karen Khar, aims to support innovation across drug development, agriculture, synthetic biology, and manufacturing.

DDavid Baker CCyrus Biotechnology UUniversity of Washington